针对慢性药物诱导性肝损伤的优化短期类固醇治疗:一个潜在的随机临床试验
Ang Huang1,2, Yun Zhu1, Shuhong Liu3
1Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
概括
对慢性药物诱导性肝损伤 (DILI) 进行36周的类固醇逐步减少 (SSR) 疗法,其疗效和安全性与48周的SSR可比,使其成为首选的治疗选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
- 内部医学 内部医学
背景情况:
- 皮质类固醇对于治疗慢性药物诱导性肝损伤 (DILI) 至关重要.
- 以前的研究表明,在慢性DILI中,48周的类固醇逐步减少 (SSR) 疗法对慢性DILI有好处.
- 较短的SSR持续时间的有效性仍需确定.
研究的目的:
- 为了比较36周的SSR疗程与48周的SSR疗程在慢性DILI患者中的疗效.
- 评估较短的SSR课程是否能达到与既定48周疗程相似的结果.
主要方法:
- 一个随机的开放标签试验,涉及90名慢性DILI的参与者.
- 患者被分配到36周或48周的SSR组.
- 主要结局是复发率 (RR);次要结局包括组织学改善和安全,在基线和治疗结束时进行肝脏活检.
主要成果:
- 在36周 (7.1%) 和48周 (4.8%) 的SSR组 (p=1.000) 中,复发率相似.
- 两组都显示出活力和纤维化的显著组织学改善.
- 两组之间没有观察到生化正常化时间或严重不良事件的差异.
结论:
- 36周的SSR疗法在实现慢性DILI的生化和组织学改善方面与48周的疗法一样有效.
- 这两种疗法都显示出良好的安全性.
- 建议采用36周的SSR疗法,因为其持续时间较短,因此它是最好的治疗选择.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
05:18Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
Published on: May 26, 2023
1.4K
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:13Therapeutic Index
4.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K